Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma
May 07 2019 - 7:00AM
In a recent study presented at the
Association for Research in Vision and Ophthalmology (ARVO) 2019
annual meeting, treatment with Lumega-Z was associated with
significant improvement in Visual Field function among patients
with severe glaucoma
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), an ocular health sciences and technologies company
that develops, formulates and distributes condition-specific
medical foods and testing technologies supported by evidence-based
protocols, today announced the results of a study from research
scientists at the University of Texas, San Antonio (USTA), Texas,
on the effects of the Company’s Lumega-Z medical food on
pericentral FDT (i.e. tests of visual field) among patients with
severe glaucoma who had previously shown degeneration despite
having controlled intraocular pressure.
Dr. David Evans, Ph.D., Guardion’s Chief Science
Officer, commenting on the results of the study, stated, “Patients
with advanced glaucoma often have no hope for maintaining their
vision. This new data, presented by Dr. William E. Sponsel, at
ARVO, shows that certain patients with advanced stages of glaucoma
treated with Lumega-Z can preserve and even recover some vision
function. This is an important development in the treatment of
patients with advanced glaucoma.”
Dr. William E. Sponsel, M.D., M.B., Ch.B,
F.R.A.N.Z.C.O, F.A.C.S., is a member of Guardion’s Science Advisory
Board. Dr. Sponsel established the Glaucoma Research and Diagnostic
Laboratory at Indiana University in 1991, and was later recruited
to the University of Texas Health Science Center at San Antonio in
1994, where he became Professor and Director of Clinical Research.
He is presently Professor of Vision Sciences at University of
Incarnate Word and Adjunct Professor of Biomedical Engineering at
UTSA.
Information and risk factors with respect to
Guardion and its business, including its ability to successfully
develop and commercialize its proprietary products and
technologies, may be obtained in the Company’s filings with the
Securities and Exchange Commission (“SEC”) at www.sec.gov.
About Guardion Health Sciences,
Inc.
Guardion is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product, Lumega-Z, that addresses a depleted
macular protective pigment, a known risk factor for age-related
macular degeneration (“AMD”) and a significant component of
functional vision performance. Guardion Health Sciences, Inc. has
also developed a proprietary medical device, the MapcatSF®, which
accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment.
About
VectorVision®
VectorVision®, operating through a wholly-owned
subsidiary of the Company, specializes in the standardization of
contrast sensitivity, glare sensitivity, low contrast acuity, and
ETDRS acuity vision testing. Its patented standardization system
provides the practitioner or researcher the ability to delineate
very small changes in visual capability, either as compared to the
population or from visit to visit. VectorVision®’s CSV-1000 device
is considered the standard of care for clinical trials.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company Contact: |
|
|
Investor Relations Contact: |
Michael Favish |
|
|
Matthew Abenante |
Chief Executive Officer |
|
|
Porter, LeVay & Rose, Inc. |
Telephone: (212) 564-4700 |
|
|
Telephone: (858) 605-9055 x 201 |
E-mail: matthew@plrinvest.com |
|
|
E-mail: mfavish@guardionhealth.com |
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2023 to Apr 2024